Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

被引：14

作者：

Foran, James M. ^{[1
]}

DiNardo, Courtney D. ^{[2
]}

Watts, Justin M. ^{[3
]}

Stein, Eytan M. ^{[4
]}

De Botton, Stephane ^{[5
]}

Fathi, Amir T. ^{[6
]}

Prince, Gabrielle T. ^{[7
]}

Stein, Anthony ^{[8
]}

Stone, Richard M. ^{[9
]}

Patel, Prapti A. ^{[10
]}

Tallman, Martin S. ^{[4
]}

Choe, Sung ^{[11
]}

Wang, Hongfang ^{[11
]}

Zhang, Vickie ^{[11
]}

Fan, Bin ^{[11
]}

Yen, Katharine E. ^{[11
]}

Oluyadi, Abdulafeez ^{[11
]}

Winkler, Thomas ^{[11
]}

Hickman, Denice ^{[11
]}

Agresta, Samuel V. ^{[11
]}

Liu, Hua ^{[11
]}

Wu, Bin ^{[11
]}

Attar, Eyal C. ^{[11
]}

Kantarjian, Hagop M. ^{[2
]}

机构：

[1] Mayo Clin Florida, Jacksonville, FL USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Inst Gustave Roussy, Villejuif, France

[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[7] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[11] Agios Pharmaceut Inc, Cambridge, MA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123946

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4254

引用

页数：4

共 50 条

[21] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT, IDH1-MUTANT, LOW-GRADE GLIOMA: RESULTS FROM COHORT 1
Mellinghoff, I. K.
Wen, P. Y.
Taylor, J. W.
Maher, E. A.
Arrillaga-Romany, I.
Peters, K. B.
Le, K.
Tai, F.
Steelman, L.
Cloughesy, T. F.
NEURO-ONCOLOGY, 2019, 21 : 2 - 2
[22] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Popovici-Muller, Janeta
Lemieux, Rene M.
Artin, Erin
Saunders, Jeffrey O.
Salituro, Francesco G.
Travins, Jeremy
Cianchetta, Giovanni
Cai, Zhenwei
Zhou, Ding
Cui, Dawei
Chen, Ping
Straley, Kimberly
Tobin, Erica
Wang, Fang
David, Muriel D.
Penard-Lacronique, Virginie
Quivoron, Cyril
Saada, Veronique
De Botton, Stephane
Gross, Stefan
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Kim, Hyeryun
Jin, Shengfang
Gu, Zhiwei
Yao, Gui
Luo, Zhiyong
Lv, Xiaobing
Fang, Cheng
Yan, Liping
Olaharski, Andrew
Silverman, Lee
Biller, Scott
Su, Shin-San M.
Yen, Katharine
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
[23] Ivosidenib in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 17 - 20
[24] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
de Botton, S.
Pollyea, D. A.
Stein, E. M.
DiNardo, C.
Fathi, A. T.
Roboz, G. J.
Collins, R.
Swords, R. T.
Flinn, I.
Altman, J. K.
Tallman, M. S.
Kantarjian, H.
Colby, K.
Fan, B.
Goldwasser, M.
Prahl, M.
Agresta, S.
Stone, R. M.
HAEMATOLOGICA, 2015, 100 : 214 - 215
[25] Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Choe, Sung
Wang, Hongfang
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Roboz, Gail J.
Altman, Jessica K.
Mims, Alice S.
Watts, Justin M.
Pollyea, Daniel A.
Fathi, Amir T.
Tallman, Martin S.
Kantarjian, Hagop M.
Stone, Richard M.
Quek, Lynn
Konteatis, Zenon
Dang, Lenny
Nicolay, Brandon
Nejad, Parham
Liu, Guowen
Zhang, Vickie
Liu, Hua
Goldwasser, Meredith
Liu, Wei
Marks, Kevin
Bowden, Chris
Biller, Scott A.
Attar, Eyal C.
Wu, Bin
BLOOD ADVANCES, 2020, 4 (09) : 1894 - 1905
[26] EXPOSURE-RESPONSE ANALYSIS OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.
Le, K.
Kleijn, H. J.
Dai, D.
Fan, B.
Liu, H.
Attar, E. C.
Hickman, D.
Agresta, S. V.
Yang, H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S85 - S85
[27] Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.
Fan, Bin
Goyal, Lipika
Lowery, Maeve Aine
Pandya, Shuchi Sumant
Manyak, Erika
Le, Kha
Jiang, Liewen
Auer, Julia
Dai, David
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS
Mellinghoff, Ingo
Cloughesy, Timothy
Wen, Patrick
Taylor, Jennie
Maher, Elizabeth
Arrillaga-Romany, Isabel
Peters, Katherine
Choi, Changho
Ellingson, Benjamin
Lin, Alexander
Thakur, Sunitha
Nicolay, Brandon
Lu, Min
Le, Kha
Yin, Feng
Tai, Feng
Schoenfeld, Steven
Pandya, Shuchi S.
Hassan, Islam
Steelman, Lori
Clarke, Jennifer
NEURO-ONCOLOGY, 2019, 21 : 28 - 28
[29] High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
Daigle, Scott R.
Choe, Sung
Quek, Lynn
DiNardo, Courtney D.
Stein, Anthony
Stein, Eytan M.
Fathi, Amir T.
Frankfurt, Olga
Schuh, Andre C.
Kantarjian, Hagop M.
Zhang, Vickie
Winkler, Thomas
Vyas, Paresh
Wu, Bin
BLOOD, 2019, 134
[30] A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN IDH1-MUTANT DIFFUSE GLIOMA: UPDATED RESULTS
Mellinghoff, Ingo
Wen, Patrick
Taylor, Jennie
Taylor, Elizabeth
Arrillaga-Romany, Isabel
Ellingson, Benjamin
Mahboub-Johnson, Paria
Baron, Eric
Hassan, Islam
Steelman, Lori
Clarke, Jennifer
Cloughesy, Timothy
NEURO-ONCOLOGY, 2024, 26

← 1 2 3 4 5 →